LEIDEN JEFFREY M 4: 3,547 shares of VRTX ($1,720,685)

Our Take

→Vertex's CEO has been a notably infrequent seller since taking the helm in 2014, making this $1.7M disposal worth parsing against his typical hold pattern. The sale represents roughly 2% of his holdings and occurs amid the company's push into new therapeutic areas beyond its CF franchise—a transition that historically creates uncertainty about near-term execution. Whether this is routine portfolio rebalancing or a signal about management confidence in the pipeline's near-term catalysts will matter more in context of Vertex's next earnings call and pipeline readouts.